What Seroba Life Sciences does

Seroba Life Sciences is a Dublin-headquartered European venture capital firm founded in 2009 that invests in early-stage biotech and medtech companies. The firm provides venture capital investment and operational support to portfolio companies developing innovative healthcare technologies, with stated focus on "value creation through backing winning innovations in biotech and medtech." Its portfolio spans gene therapy (Complement Therapeutics, Coave Therapeutics, Covagen), medical devices for stroke treatment and surgical intervention (Perfuze, Ryme Medical, Veryan-Med, Novate), dialysis technology (Quanta Dialysis Technologies), neurology (Sibylla, Shiratronics), and AI-enabled diagnostics (Deciphex).

Seroba's business model is that of a traditional venture capital partnership. Revenue is generated through fund management fees on committed capital and carried interest on portfolio exits; the firm does not disclose pricing or revenue publicly. The firm is backed by institutional limited partners including the European Investment Fund, CDP Venture Verticals, Enterprise Ireland, and the National Treasury Management Agency (NTMA), and maintains memberships in Invest Europe, the Irish Venture Capital Association, and the Principles for Responsible Investment. Distribution of capital is conducted through direct investment relationships with portfolio companies, primarily across Ireland and broader European markets.

The firm differentiates through complementary investment and operational industry expertise across an 11-person team of partners and specialists. Unlike a product company, Seroba does not develop proprietary technology; its value proposition rests on capital deployment, strategic guidance, industry connections, and operational support for portfolio companies addressing funding and scaling gaps in European life sciences innovation.

Name

Seroba Life Sciences

Legal name

Seroba Life Sciences

Website

https://seroba-lifesciences.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Seroba Life Sciences is a Dublin-based European venture capital firm founded in 2009 that invests venture capital and provides operational support to early-stage biotech and medtech companies across Europe, backed by institutional LPs including the EIF, CDP Venture, Enterprise Ireland, and NTMA.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Miscellaneous Financial Investment Activities (523999)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Venture capital investing
• Life sciences investment
• Biotech venture capital
• Medtech investment
• Portfolio company funding

Headquarters

HQ city

Dublin

HQ country

Ireland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Distribution channels1 record

Marketing channels4 records

Core offering

Seroba Life Sciences is a European life sciences venture capital firm that invests equity capital and provides operational support to early-stage biotech and medtech companies developing innovative science-based healthcare solutions. The firm generates returns through portfolio company exits, fund management fees, and carried interest, and is backed by institutional limited partners including the European Investment Fund, CDP Venture, Enterprise Ireland, and the NTMA.

Product overview

Seroba is a European life sciences venture capital firm, not a product company. As a VC firm, it does not develop or offer its own technology products or services. Seroba backs portfolio companies in the biotech and medtech sectors including Shiratronics, Ryme Medical, Sibylla, Coave Therapeutics, Quanta Dialysis Technologies, Veryan-Med, Novate, and Covagen, among others. These portfolio companies develop their own distinct products in areas such as stroke treatment catheters, gene therapies, dialysis technologies, and medical devices. Seroba's role is investment and operational support rather than product development.

Differentiator

Problem solved

Functional benefit

Products and services

• European life sciences venture capital fund (general category) Venture capital fund management services that deploy equity capital into early-stage European biotech and medtech companies and provide operational support, strategic guidance, and industry connections; the fund is backed by institutional limited partners including the European Investment Fund, CDP Venture Vertical, Enterprise Ireland, and the National Treasury Management Agency.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and minor.

• Invest EuropecoreOthersSeroba is a member of Invest Europe and has contributed to developing the organization's position paper on Biotech and Healthcare: The Venture Capital and Private Equity Perspective, working alongside BGV and Hadean to shape European venture capital policy and industry standards.
• Irish Venture Capital Association (IVCA)coreOthersSeroba is a member of the Irish Venture Capital Association (IVCA), the leading body representing venture capital and private equity firms in Ireland.
• Principles for Responsible Investment (PRI)minorOthersSeroba is a signatory to the Principles for Responsible Investment (PRI), demonstrating commitment to responsible investment practices in the life sciences sector.

Recent moves5 records

Expansion highlights4 records

Direct peers

• Forbion: Forbion is a leading European life sciences venture capital firm investing in biotech and medtech. It is a direct peer to Seroba, competing for the same European biotech deal flow with a larger fund base and a similar thesis of building biotech companies around breakthrough science.
• BioGeneration Ventures (BGV): BGV is a Dutch-based European venture capital firm focused on early-stage biotech. BGV is a direct peer to Seroba — they co-led Invest Europe's biotech position paper together, operate at similar fund sizes, and target the same European biotech startup segment.
• Sofinnova Partners: Sofinnova Partners is one of Europe's largest healthcare and life sciences VC firms, investing across biotech and medtech from early to late stage. It is a direct peer operating in the same European life sciences VC category as Seroba, though typically at larger fund sizes.
• Hadean Ventures: Hadean Ventures is a Nordic/European life sciences VC firm investing in biotech and medtech. It is a direct peer to Seroba — they co-developed the Invest Europe position paper together and share a similar European regional focus.
• Gilde Healthcare: Gilde Healthcare is a Netherlands-based European healthcare VC firm investing across therapeutics, medtech, and digital health. It is a direct peer to Seroba, targeting similar European biotech/medtech founders with comparable ticket sizes.
• LSP (Life Sciences Partners): LSP is a long-established European life sciences VC firm investing across all stages of biotech and medtech. It is a direct peer to Seroba in the European life sciences VC category, with deeper AUM and broader stage focus.
• Andera Partners: Andera Partners (formerly Edmond de Rothschild Investment Partners) operates a dedicated life sciences venture franchise in Europe. It is a direct peer to Seroba, competing for European biotech and medtech deals across similar stages.
• Kurma Partners: Kurma Partners is a Paris-based European life sciences VC firm investing in biotech and digital health. It is a direct peer to Seroba, sharing the European focus and life sciences specialty, with overlapping geographies and target company profiles.

Broad incumbents

• Eli Lilly European Venture Fund / Lilly Ventures-type corporate VCs: Corporate venture arms of large pharma (Lilly, Novartis, Roche) are broader incumbents in the European life sciences investment space. They participate in the same syndicates as Seroba at the growth stage but with much larger balance sheets and strategic commercial interests.

Others

• Enterprise Ireland (Growth Capital / Seed Funds): Enterprise Ireland is one of Seroba's key institutional LPs but also operates direct investment programs supporting Irish and European life sciences startups. It is an adjacent ecosystem player — both LP to and investor alongside Seroba in the same companies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/serobavc

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments49 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seroba Life Sciences